Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of NAT2 Genetic Variations on Anti-Tuberculosis Drug-Induced Liver Injury
TCTR20260619004Completed
- Sponsor
- N/A
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of isoniazid in Tuberculosis (TB), sponsored by N/A. Primary endpoint: Incidence of anti-tuberculosis drug-induced liver injury. Started Dec 2025; status: completed.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on TCTR20260619004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260619004.